Ticilimumab. Anti-CTLA-4 antibody, oncolytic

Drugs of the Future

Volumn 32, Issue 4, 2007, Pages 337-340

  Wang, Y ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CP 675206; DACARBAZINE; INTERLEUKIN 10; INTERLEUKIN 12; MELAN A; SUNITINIB; TEMOZOLOMIDE; TICILIMUMAB; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CELL INFILTRATION; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DERMATITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; PRURITUS; URTICARIA;

EID: 34347371807     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.04.1089088     Document Type: Article

References (36)

1. Linsley, P.S., Brady, W., Grosmaire, L.S., Aruffo, A., Damle, N.K., Ledbetter, J.A. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991, 173(3): 721-30.
2. Hathcock, K.S., Laszlo, G., Dickler, H.B., Bradshaw, J., Linsley, P., Hodes, R.J. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 1993, 262: 905-7.
3. Jenkins, M.K., Taylor, P.S., Norton, S.D., Urdahl, K.B. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991, 147(8): 2461-6.
4. Harding, F., McArthur, J.G., Gross, J.A., Raulet, D.H., Allison, J.P. CD28 mediated signaling costimulates murine T cells and prevents the induction of anergy in T cell clones. Nature 1992, 356: 607-9.
5. Lenschow, D.J., Walunas, T.L., Bluestone, J.A. CD28/B7 system of T cell costimulation. Ann Rev Immunol 1996, 14: 233-58.
6. Brunet, J.F., Denizot, F., Luciani, M.F. et al. A new member of the immunoglobulin superfamily - CTLA-4. Nature 1987, 328: 267-70.
7. Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L.S., Damle, N.K., Ledbetter, J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991, 174(3): 561-9.
8. Walunas, T.L., Lenschow, D.J., Bakker, C.Y. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1(5): 405-13.
9. Krummel, M.F., Allison, J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182(2): 459-65.
10. Read, S., Malmstrom, V., Powrie, F. Cytotoxic T lymphocyte-associated antigen plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000, 192(2): 295-302.
11. Salomon, B., Lenschow, D.J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. Bluestone, J.A. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12(4): 431-40.
12. Chambers, C.A., Kuhns, M.S., Egen, J.G., Allison, J.P. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001, 19: 565-94.
13. Waterhouse, P., Penninger, J.M., Timms, E. et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995, 270: 985-8.
14. Tivol, E.A., Borriello, F., Schweitzer, A.N., Lynch, W.P., Bluestone, J.A., Sharpe, A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3(5): 541-7.
15. Leach, D.R., Krummel, M.F., Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271: 1734-6.
16. Hodi, F.S., Mihm, M.C., Soiffer, R.J. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003, 100(8): 4712-7.
17. Sanderson, K., Scotland, R., Lee, P. et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T lymphocyte antigen-4-monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005, 23(4): 741-50.
18. Phan, G.O., Sherry, R.M., Hwu, P. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003, 100(14): 8372-7.
19. Hanson, D.C., Canniff, P.C., Primiano, M.J. et al. Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 3802.
20. Canniff, P.C., Bonovan, C.B., Burkwit, J.J., Bruns, M.J., Bedian, V., Bernstein, S.H., Hanson, D.C. CP-675,206 anti-CTLA4 antibody clinical candidate enhances IL-2 production in cancer patient T cells in vitro regardless of tumor type or stage of disease. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 709.
21. Millham, R., Pavlov, D., Canniff, P. et al. Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206). 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 2542.
22. Ribas, A., Camacho, L.H., Lopez-Berestein, G. et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005, 23(35): 8968-77.
23. Ribas, A., Bozon, VA., Lopez-Berestein, G. et al. Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 7524.
24. Ribas, A., Bozon, V., Lopez-Berestein, G. et al. Monthly dosing of the human anti-CTLA4 monoclonal antibody CP-675,206 (ticilimumab) in patients with advanced melanoma: Phase 1 trial. 6th World Congr Melanoma (Sept 8-10, Vancouver) 2005, Abst P-161.
25. Gomez-Navarro, J., Sharma, A., Bozon, V. et al. Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 8032.
26. Bulanhagui, C.A., Ribas, A., Pavlov, D. et al. Phase I clinical trials of ticilimumab: Tumor responses are sufficient but not necessary for prolonged survival. 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 8036.
27. Reuben, J.M., Lee, B.N., Shen, D.Y. et al. Therapy with human monoclonal anti-CTLA-4 antibody, CP-675,206, reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (MM). 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 7505.
28. Reuben, J.M., Lee, B.-N., Li, C. et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006, 106(11): 2437-44.
29. Noe, D.A., Sharma, A. Potential determinants of clinical efficacy of ticilimumab in melanoma. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst C30.
30. A study of ticilimumab in patients with metastatic colorectal cancer whose disease had progressed after treatment (NCT00313794). ClinicalTrials.gov Web site, April 10, 2007.
31. Phase 2 randomized study of CP-675,206 or best supportive care immediately after platinum-based therapy for NSCLC (NCT00312975). ClinicalTrials.gov Web site, April 10, 2007.
32. Phase 3 trial of CP-675,206 versus either dacarbazine or temozolomide in patients without prior therapy (NCT00257205). ClinicalTrials.gov Web site. April 10, 2007.
33. Dose-finding study of CP-675,206 and SU011248 in patients with metastatic renal cell carcinoma not previously treated (NCT00372853). ClinicalTrials.gov Web site, April 10, 2007.
34. CP-675,206 (CTLA4-blocking monoclonal antibody) combined with dendritic cell vaccine therapy in treating patients with stage III or stage IV melanoma that cannot be removed with surgery (NCT00090896). ClinicalTrials.gov Web site, April 10, 2007.
35. Ribas, A., Comin-Anduix, B., Bozon, V. et al. Antigen-specific T cell responses in patients with melanoma treated with the CTLA4-blocking mAb CP-675,206. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 8033.
36. Kapadia, D., Fong, L. CTLA-4 blockade: Autoimmunity as treatment. J Clin Oncol 2005, 23(35): 8926-8.